Global guidelines for treatment of tuberculosis among persons living with HIV: Unresolved issues

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 573-578

  Kumar, Ajay ^a   Kumar, A M V ^a,b   Gupta, D ^a   Kanchar, A ^a   Mohammed, S ^a   Srinath, S ^c   Tripathy, S ^d   Rajasekaran, S ^a   Chan, P L ^b   Swaminathan, S ^e   Dewan, P K ^b  

^a GOVERNMENT OF INDIA   (India)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d NATIONAL AIDS RESEARCH INSTITUTE   (India)

^e NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

ART; HIV; India; Intermittent regimen; TB

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; DIRECTLY OBSERVED THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MIXED INFECTION; MOLECULAR EPIDEMIOLOGY; MORTALITY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REINFECTION; SHORT COURSE THERAPY; SHORT SURVEY; TREATMENT OUTCOME; TUBERCULOSIS;

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; INDIA; MOLECULAR EPIDEMIOLOGY; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84859703493     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0482     Document Type: Short Survey

References (36)

1. Central TB Division. Technical and operations guidelines for tuberculosis control. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2005. http://www.tbcindia.org/ documents.asp Accessed February 2012.
2. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/ publications/tb-treatmentguidelines/en/index.html Accessed February 2012.
3. Khan F A, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and metaanalysis. Clin Infect Dis 2010; 50: 1288-1299.
4. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-751.
5. Grimes D A, Schulz K F. An overview of clinical research: the lay of the land. Lancet 2002; 359: 57-61. (Pubitemid 34119200)
6. Lambert M L, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-287. (Pubitemid 36565879)
7. Harries A D, Zachariah R, Corbett E L, et al. The HIV-associated tuberculosis epidemic - when will we act? Lancet 2010; 375: 1906-1919.
8. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693. (Pubitemid 33124328)
9. Charalambous S, Grant A D, Moloi V, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008; 12: 942-948.
10. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 2010; 201: 691-703.
11. El-Sadr W M, Perlman D C, Matts J P, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26: 1148-1158. (Pubitemid 28215480)
12. Li J, Munsiff S S, Driver C R, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41: 83-91. (Pubitemid 40863749)
13. Nahid P, Gonzalez L C, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206. (Pubitemid 46855463)
14. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847. (Pubitemid 29251017)
15. Golub J E, Durovni B, King B S, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22: 2527-2533.
16. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53: 716-724.
17. Central TB Division. TB India 2011. Revised National TB Control Programme annual status report. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2011. http://www.tbcindia.org/pdfs/RNTCP%20TB%20India%202011.pdf Accessed February 2012.
18. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011. http://www.who.int/tb/ publications/2011-TBreport-launch/en/index.html
19. Kumar A M, Gupta D, Rewari B B, et al. Will adoption of the 2010 WHO ART guidelines for HIV-infected TB patients increase the demand for ART services in India? PLoS One 2011; 6: e24297.
20. Vijayashree H Y, Kumaraswamy L, Karadiguddi C C. Identification of correlates for not reaching the ART centre in TB-HIV co-infected patients. Int J Tuberc Lung Dis 2011; 15 (Suppl 3): S83. [Abstract]
21. Abdool Karim S S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
22. Blanc F X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471-1481.
23. Havlir D V, Kendall M A, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-1491.
24. Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS, 2008.
25. Naik B R, Lal K, Doddamani D D, et al. HIV seroprevalence among tuberculosis suspects in Mandya District, South India, 2010. Int J Tuberc Lung Dis 2011; 15 (Suppl 3): S199. [Abstract]
26. Tuberculosis Chemotherapy Centre Madras. Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. BMJ (Clin Res Ed) 1973; 2: 7-11.
27. Pasipanodya J G, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 2010; 54: 2847-2854.
28. Parthasarathy R, Sarma G R, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67: 99-108. (Pubitemid 16080227)
29. Hong Kong Chest Service/British Medical Research Council. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle 1976; 57: 81-95.
30. Abdool Karim Q, Abdool Karim S S, Baxter C, et al. The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J 2010; 100: 808-809.
31. Dewan P K, Gupta D, Williams B G, et al. National estimate of HIV seroprevalence among tuberculosis patients in India. Int J Tuberc Lung Dis 2010; 14: 247-249.
32. National AIDS Control Organization. HIV estimates for India 2009. New Delhi, India: Ministry of Health and Family Welfare, Government of India, 2010. http://www.nacoonline.org/upload/HomePage/ NACO%20Press%20Release%20on%20HIV%20Estimates.pdf Accessed February 2012.
33. Raizada N, Chauhan L S, Khera A, et al. HIV seroprevalence among tuberculosis patients in India, 2006-2007. PLoS One 2008; 3: e2970.
34. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
35. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000150.
36. National AIDS Research Institute. Technical report of national consultation: 'Galvanizing evidence for policy change'. Pune, India: NARI, 2011.